{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:03:29Z","timestamp":1788447809527,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA048617"],"award-info":[{"award-number":["R01DA048617"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pbb.2022.173466","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T12:58:46Z","timestamp":1663765126000},"page":"173466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans"],"prefix":"10.1016","volume":"220","author":[{"given":"William W.","family":"Stoops","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon R.","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abner O.","family":"Rayapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Lile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173466_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0091-3057(96)00445-5","article-title":"A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement","volume":"57","author":"Arnold","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173466_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.irn.2017.06.006","article-title":"Orexin\/hypocretin system: role in food and drug overconsumption","volume":"136","author":"Barson","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"9","key":"10.1016\/j.pbb.2022.173466_bb0015","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/ejn.12866","article-title":"Orexin-1 receptor signaling increases motivation for cocaine-associated cues","volume":"41","author":"Bentzley","year":"2015","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/adb.12553","article-title":"Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine","volume":"23","author":"Bernstein","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2022.173466_bb0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.drugalcdep.2017.05.039","article-title":"N-acetylcysteine reduces cocaine cue attentional bias and differentially alters cocaine self-administration based on dosing order","volume":"178","author":"Bolin","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"36","key":"10.1016\/j.pbb.2022.173466_bb0030","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1523\/JNEUROSCI.6096-08.2009","article-title":"Orexin A\/hypocretin-1 selectively promotes motivation for positive reinforcers","volume":"29","author":"Borgland","year":"2009","journal-title":"J. Neurosci."},{"issue":"15","key":"10.1016\/j.pbb.2022.173466_bb0035","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.bmcl.2015.05.012","article-title":"Recent trends in orexin research\u20132010 to 2015","volume":"25","author":"Boss","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2022.173466_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnbeh.2013.00059","article-title":"The hypocretins and the reward function: what have we learned so far?","volume":"7","author":"Boutrel","year":"2013","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbr.2015.05.051","article-title":"Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep","volume":"291","author":"Brodnik","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173466_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2022.173466_bb0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2022.173466_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/add.14821","article-title":"The relevance of animal models of addiction","volume":"115","author":"Deroshe-Gamonet","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173466_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0376-8716(02)00327-7","article-title":"Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval and magnitude of alternative reinforcement","volume":"69","author":"Donny","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(97)00054-9","article-title":"Dissociation between subjective and behavioral responses after cocaine stimuli presentations","volume":"47","author":"Dudish-Poulsen","year":"1997","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/sleep\/4.1.93","article-title":"The St. Mary's hospital sleep questionnaire: a study of reliability","volume":"4","author":"Ellis","year":"1981","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.pbb.2022.173466_bb0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-010-2048-8","article-title":"Hypocretin 1\/orexin a in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration","volume":"214","author":"Espa\u00f1a","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.14764","article-title":"Are animal models of addiction useful?","volume":"115","author":"Field","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173466_bb0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0376-8716(94)01085-Y","article-title":"Cardiovascular effects of cocaine in humans: laboratory studies","volume":"37","author":"Foltin","year":"1995","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173466_bb0095","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.drugalcdep.2018.04.018","article-title":"Hypocretin\/orexin antagonists decrease cocaine self-administration by female rhesus monkeys","volume":"188","author":"Foltin","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173466_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbb.2015.03.023","article-title":"Development of translational preclinical models in substance abuse: effects of cocaine administration on cocaine choice in humans and non-human primates","volume":"134","author":"Foltin","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173466_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neubiorev.2018.03.020","article-title":"Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder","volume":"89","author":"Galaj","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.pbb.2022.173466_bb0115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/npp.2017.158","article-title":"Effects of suvorexant, a dual orexin\/hypocretin receptor antagonist, on impulsive behavior associated with cocaine","volume":"43","author":"Gentile","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-011-2231-6","article-title":"Aripioprazole maintenance increases smoked cocaine self-administration in humans","volume":"216","author":"Haney","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0125","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2022.173466_bb0130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.pbb.2022.173466_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnbeh.2012.00047","article-title":"Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence","volume":"6","author":"Hollander","year":"2012","journal-title":"Front. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.pbb.2022.173466_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.npep.2013.10.009","article-title":"Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?","volume":"47","author":"Hoyer","year":"2013","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pbb.2022.173466_bb0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/09658211003702171","article-title":"The concurrent validity of the N-back task as a working memory measure","volume":"18","author":"Jaeggi","year":"2010","journal-title":"Memory"},{"key":"10.1016\/j.pbb.2022.173466_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108359","article-title":"The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse","volume":"183","author":"James","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/7854_2016_57","article-title":"A decade of orexin\/hypocretin and addiction: where are we now?","volume":"33","author":"James","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10550490601184142","article-title":"Neurobiology of addiction: implications for new pharmacotherapy","volume":"16","author":"Kalivas","year":"2007","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pbb.2022.173466_bb0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00008877-199000140-00003","article-title":"Models of relative reinforcing efficacy of drugs and their predictive utility","volume":"1","author":"Katz","year":"1990","journal-title":"Behav. Pharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2022.173466_bb0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40263-014-0179-x","article-title":"Orexin\/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?","volume":"28","author":"Khoo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2022.173466_bb0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1037\/a0035973","article-title":"A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute","volume":"22","author":"Koffarnus","year":"2014","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173466_bb0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1523\/JNEUROSCI.23-01-00007.2003","article-title":"Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins\/hypocretins","volume":"23","author":"Korotkova","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0000000000001562","article-title":"Cognitive effects of the dual orexin receptor antagonist lemborexant compared with suvorexant and zolpidem in recreational sedative users","volume":"42","author":"Landry","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173466_bb0195","first-page":"491","article-title":"Suvorexant: a promising, novel treatment for insomnia","volume":"12","author":"Lee-Iannotti","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"18","key":"10.1016\/j.pbb.2022.173466_bb0200","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00213-017-4673-y","article-title":"Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling","volume":"234","author":"Levy","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1037\/pha0000302","article-title":"Pharmacological validation of a translational model of cocaine use disorder: effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys","volume":"28","author":"Lile","year":"2020","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173466_bb0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drugalcdep.2016.05.022","article-title":"Development of a translational model to screen medications for cocaine use disorder II: choice between intravenous cocaine and money in humans","volume":"165","author":"Lile","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173466_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0033291799001269","article-title":"Attentional bias for drug cues in opiate dependence","volume":"30","author":"Lubman","year":"2000","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.pbb.2022.173466_bb0225","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/add.12635","article-title":"Fixation time is a sensitive measure of cocaine cue attentional bias","volume":"109","author":"Marks","year":"2014","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.pbb.2022.173466_bb0230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/WNR.0000000000000120","article-title":"Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking","volume":"25","author":"Martin-Fardon","year":"2014","journal-title":"Neuroreport"},{"key":"10.1016\/j.pbb.2022.173466_bb0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/400_2007_047","article-title":"Orexins and orexin receptors: from molecules to integrative physiology","volume":"46","author":"Matsuki","year":"2008","journal-title":"Results Probl. Cell Differ."},{"key":"10.1016\/j.pbb.2022.173466_bb0240","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1152\/jn.00452.2021","article-title":"Intranasal orexin a modulates sympathetic vascular tone: a pilot study in healthy male humas","volume":"137","author":"Meusel","year":"2022","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.pbb.2022.173466_bb0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/add.14788","article-title":"Lasting translation: how to improve animal models for addiction treatment","volume":"115","author":"Muller","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173466_bb0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/NSS.S76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant","volume":"8","author":"Norman","year":"2016","journal-title":"Nat Sci Sleep"},{"issue":"3","key":"10.1016\/j.pbb.2022.173466_bb0255","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-3565(25)11160-9","article-title":"Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports","volume":"261","author":"Oliveto","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173466_bb0260","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41386-021-01173-5","article-title":"Orexin-1 receptor signaling in ventral tegmental area mediates cue-driven demand for cocaine","volume":"47","author":"Pantazis","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnbeh.2012.00082","article-title":"Local hypocretin-1 modulates terminal dopamine concentration in the nucleus accumbens shell","volume":"6","author":"Patyal","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/add.14790","article-title":"An imperfect model is still useful","volume":"115","author":"Perry","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173466_bb0275","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41386-018-0008-x","article-title":"Environmental, genetic and epigenetic contributions to cocaine addiction","volume":"43","author":"Pierce","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/cn500246j","article-title":"Hypocretin\/orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1","volume":"6","author":"Prince","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2022.173466_bb0285","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jeab.744","article-title":"Clinical neuropharmacology of cocaine reinforcement: a narrative review of human laboratory self-administration studies","volume":"117","author":"Regnier","year":"2022","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.pbb.2022.173466_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"1996","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1124\/jpet.102.048439","article-title":"Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans","volume":"306","author":"Rush","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173466_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108413","article-title":"Topiramate-phentermine combinations reduce cocaine self-administration in humans","volume":"218","author":"Rush","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173466_bb0305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/JCP.0b013e3181d21967","article-title":"Cocaine choice in humans during d-amphetamine maintenance","volume":"30","author":"Rush","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173466_bb0310","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guidelines for the pharmacologic treatment of chronic insomnia in adults: an American Academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J. Clin. Sleep Med."},{"issue":"7","key":"10.1016\/j.pbb.2022.173466_bb0315","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.biopsych.2016.06.010","article-title":"Hypocretin neurotransmission within the central amygdala mediates escalated cocaine self-administration and stress-induced reinstatement in rats","volume":"81","author":"Schmeichel","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173466_bb0320","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/s41386-018-0054-4","article-title":"Knockdown of hypocretin attenuates extended access of cocaine self-administration in rats","volume":"43","author":"Schmeichel","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pbb.2022.173466_bb0325","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/adb.12432","article-title":"Hypocretin\/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine","volume":"22","author":"Shaw","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2022.173466_bb0330","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0306-4603(82)90005-3","article-title":"The drug abuse screening test","volume":"7","author":"Skinner","year":"1982","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pbb.2022.173466_bb0335","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s002130050702","article-title":"Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review","volume":"139","author":"Stafford","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0345","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.apha.2021.07.001","article-title":"Human behavioral pharmacology of stimulant drugs: an update and narrative review","volume":"93","author":"Strzelecki","year":"2022","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173466_bb0340","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1017\/S1461145712000193","article-title":"The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat","volume":"16","author":"Steiner","year":"2013","journal-title":"Int. J. Neuropscyhopharmacol."},{"key":"10.1016\/j.pbb.2022.173466_bb1000","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuropharm.2018.02.010","article-title":"Hypocretin\/orexin deficiency decreases cocaine abuse liability","volume":"133","author":"Steiner","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0350","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1360-0443.2011.03766.x","article-title":"Influence of acute bupropion pre-treatment on the effects of intranasal cocaine","volume":"107","author":"Stoops","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173466_bb0355","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00213-019-05227-x","article-title":"Influence of phendimetrazine maintenance on the reinforcing, subjective, performance and physiological effects of intranasal cocaine","volume":"236","author":"Stoops","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173466_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146359","article-title":"Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder","volume":"1731","author":"Suchting","year":"2020","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0365","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130100764","article-title":"Attentional bias associated with alcohol cues: differences between heavy and occasional social drinkers","volume":"157","author":"Townshend","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173466_bb0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2009.07.011","article-title":"Cocaine abuse versus cocaine dependence: cocaine self-administration and pharmacodynamic response in the human laboratory","volume":"106","author":"Walsh","year":"2010","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.pbb.2022.173466_bb0375","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.neuropharm.2012.07.044","article-title":"Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats","volume":"63","author":"Zhou","year":"2012","journal-title":"Neuropharmacology"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:23Z","timestamp":1758775403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":76,"alternative-id":["S0091305722001459"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173466","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173466"}}